Prothena Corporation PLC (PRTA) Position Lifted by Rhumbline Advisers

Rhumbline Advisers increased its holdings in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 6.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,262 shares of the biotechnology company’s stock after acquiring an additional 2,936 shares during the period. Rhumbline Advisers owned approximately 0.12% of Prothena Corporation PLC worth $2,450,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. acquired a new position in Prothena Corporation PLC during the first quarter worth $588,000. BlackRock Inc. grew its holdings in Prothena Corporation PLC by 95,458.7% during the first quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock worth $152,526,000 after acquiring an additional 2,731,073 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in Prothena Corporation PLC during the first quarter worth $273,000. Thrivent Financial For Lutherans grew its holdings in Prothena Corporation PLC by 15.8% during the first quarter. Thrivent Financial For Lutherans now owns 37,170 shares of the biotechnology company’s stock worth $2,074,000 after acquiring an additional 5,070 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in Prothena Corporation PLC by 12.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 153,857 shares of the biotechnology company’s stock worth $8,584,000 after acquiring an additional 16,665 shares during the period.

A number of research analysts recently weighed in on PRTA shares. ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research raised Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Friday, August 11th. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Prothena Corporation PLC in a report on Thursday, July 6th. Finally, BTIG Research started coverage on Prothena Corporation PLC in a report on Friday, May 19th. They set a “buy” rating and a $80.00 price objective on the stock. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $77.58.

TRADEMARK VIOLATION WARNING: This story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/09/13/prothena-corporation-plc-prta-position-lifted-by-rhumbline-advisers.html.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at 62.38 on Wednesday. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $69.53. The firm’s 50-day moving average price is $59.72 and its 200-day moving average price is $56.03. The stock’s market capitalization is $2.39 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same period last year, the firm earned ($1.18) EPS. The firm’s revenue for the quarter was up 7951.1% on a year-over-year basis. Equities analysts forecast that Prothena Corporation PLC will post ($4.52) earnings per share for the current fiscal year.

In other news, Director Dennis J. Selkoe sold 3,500 shares of Prothena Corporation PLC stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares in the company, valued at approximately $368,707.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of Prothena Corporation PLC stock in a transaction on Monday, July 17th. The shares were sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by company insiders.

Prothena Corporation PLC Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply